BROMDAY Drug Patent Profile
✉ Email this page to a colleague
When do Bromday patents expire, and when can generic versions of Bromday launch?
Bromday is a drug marketed by Bausch And Lomb Inc and is included in one NDA.
The generic ingredient in BROMDAY is bromfenac sodium. Ten suppliers are listed for this compound. Additional details are available on the bromfenac sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bromday
A generic version of BROMDAY was approved as bromfenac sodium by SENTISS on January 22nd, 2014.
Summary for BROMDAY
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 88 |
Clinical Trials: | 4 |
Patent Applications: | 4,765 |
What excipients (inactive ingredients) are in BROMDAY? | BROMDAY excipients list |
DailyMed Link: | BROMDAY at DailyMed |
Recent Clinical Trials for BROMDAY
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sun Pharma Global FZE | Phase 2 |
InSite Vision | Phase 2 |
Virdi Eye Clinic |
Anatomical Therapeutic Chemical (ATC) Classes for BROMDAY
US Patents and Regulatory Information for BROMDAY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | BROMDAY | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-002 | Oct 16, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BROMDAY
See the table below for patents covering BROMDAY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 609932 | ⤷ Try a Trial | |
Germany | 68902649 | ⤷ Try a Trial | |
Philippines | 26827 | A locally administrable therapeutic composition for inflammatory disease | ⤷ Try a Trial |
Australia | 2878689 | ⤷ Try a Trial | |
South Korea | 960005707 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BROMDAY
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1586316 | SPC/GB11/054 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523 |
1586316 | 2011C/027 | Belgium | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC; AUTHORISATION NUMBER AND DATE: EU/1/11/692/001 20110523 |
1586316 | 11C0031 | France | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
1586316 | 132011901975261 | Italy | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC(YELLOX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/692/001, 20110518 |
1586316 | 122011100019 | Germany | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |